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Introduction 
 
The decline in cognitive function witnessed in older adults is associated with a number of 
physiological changes which occur in the brain during ageing. For example, both white and 
grey matter brain volumes gradually decrease in older adults and overall cerebral per- 
fusion is reduced, resulting in poorer delivery of nutrients and energy. The development of 
neurofibrillary tangles and amyloid plaques also contributes towards neuronal loss. 
Observational studies at the epidemiological level have suggested that individuals with an 
increased dietary intake of oily fish and other foods rich in the omega-3 polyunsaturated 
fatty acids (n-3 PUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have 
better long-term cognitive outcomes and lower incidences of dementia [1]. Further, a 
positive association between levels of DHA in blood markers (e.g. red blood cells and 
plasma phospholipids) and better performance on tasks of visual memory, abstract skills, 
executive function as well as total cerebral brain volume has also been observed [2]. Both 
DHA and EPA have numerous roles in the body which may impact the overall health and 
function of the brain, and consequently attenuate cognitive decline. It is known that 
DHA comprises around 40% of total PUFAs in the brain; incorporation of DHA in cell 
membrane phospholipids contributes to maintaining the structural integrity of neuronal 
cell membranes and the formation of lipid rafts which in turn affects numerous signalling 
pathways and neurotransmitter systems. EPA may influence brain function indirectly via the 
action of EPA-derived signalling molecules – termed eicosanoids – which are known to 
regulate inflammatory processes and immune responses. It has also been suggested that 
the positive effects of dietary n-3 PUFAs in promoting the brain’s overall structural 
integrity and function, namely ‘brain health’, may be related, at least in part, to enhanced 
cardiovascular functioning, specifically via increased blood flow to the brain, as a result of 
the effect of n-3 PUFAs on the cardiovascular system [1, 3]. 
 
Cerebral Blood Flow and Cognition 
 
It is known that brain activity depends on a constant supply of oxygen and glucose which 
are delivered, as required, via the blood. Even though cerebral metabolic demands are 
comparatively very high, the brain actually has restricted means of energy storage. 
Therefore, local brain activity must be matched by an associated increase in local cerebral 
blood flow (CBF), a phenomenon referred to as neurovascular coupling. Early hypotheses 
of the relationship between neuronal metabolism and local circulation proposed that 
increased energy use and/or oxygen consumption of neurons (as a consequence of 
increased cognitive activity) directly triggered vasodilation. However, although increases in 
CBF appear quickly in response to increased neural activity, metabolic changes occur 
more slowly, indicating that the nature of neuron-to-vessel signal- ling is more complex. 
Overall this suggests that blood flow changes may occur through several intermediate 
steps, rather than by direct increases in neuronal activity. These steps include the 
signalling activities of nitric oxide (NO) which regulates neuronal transmission and the 
release of neurotransmitters which result in smooth muscle relaxation and vasodilation in 
the brain. Numerous similar signalling processes are also believed to take place, but these 
are complex and still under investigation. 
 
N-3 PUFAs and Cerebral Blood Flow 
 
The effect of DHA and EPA on the cardiovascular system has been a topic of intense 
investigation. For example, blood concentrations of epinephrine and norepinephrine have 
been shown to be lowered by DHA and EPA supplementation, while improvements in 
haemorheology through fish oils have also been shown [1]. Further evidence obtained 
from both animal and human studies suggests that n-3 PUFAs beneficially affect several 
cardiovascular processes, including improved endothelial function, promotion of 
vasodilatation via relaxation of smooth muscle cells, delayed development of plaques, 
antioxidant properties, anti-inflammatory proper- ties and decreased stiffening of arterial 
walls [4]. Current evidence also supports the hypothesis that increased dietary intake of 
n-3 PUFAs decreases blood pressure in hypertensive patients, however, this effect is 
reduced in individuals whose n-3 PUFA status is higher prior to supplementation [4]. Given 
these observed effects of n-3 PUFAs on cardiovascular parameters, it seems rational to 
assume that n-3 PUFAs may exert secondary effects on brain function and overall brain 
health via modulation of cerebral haemodynamics. It may also be that the previously 
observed attenuation in cognitive decline during normal ageing may result from 
improved cerebrovascular function, an assessment of which can be made via several 
neuroimaging  techniques. 
 
 
CBF Neuroimaging Techniques 
 
The most widely used non-invasive neuroimaging techniques in the assessment of cerebral 
haemodynamics are functional magnetic resonance imaging (fMRI) and near-infrared 
spectroscopy (NIRS). 
 
Functional magnetic resonance imaging (fMRI) 
 
Functional activations in the brain can be detected with MRI via direct measurements of 
tissue perfusion, blood oxygenation and blood volume. Cerebral haemodynamic activity is 
usually mapped using an intravascular contrast agent, such as Magnevist (a lanthanide-
gadolinium chelate). When the blood-brain barrier (BBB) is intact, the contrast agent is 
confined to the intravascular space, and this compartmentalisation is the basis of the 
observed magnetic susceptibility effects in the surrounding tissues, allowing for the 
accurate estimation of regional cerebral blood volume (rCBV). 
The functional images utilise the blood-oxygen-level dependent (BOLD) contrast, which 
depicts differences in blood oxygenation. Almost all non-invasive fMRI is possible because 
blood haemoglobin is diamagnetic (counteracts the magnetic field) when it is oxygenated 
and paramagnetic (enhances the magnetic field) when it is deoxygenated. This allows for 
the measurement of the amounts of both oxygenated and deoxygenated haemoglobin 
within the brain, offering insights into localised increases in neuronal activation through 
the metabolic consumption of oxygen within the brain. 
 
Near-infrared spectroscopy (NIRS) 
 
Near-Infrared Spectroscopy (NIRS) is a neuroimaging technique that measures the 
amounts of both oxygenated (oxy-Hb) and de- oxygenated (deoxy-Hb) haemoglobin 
following the introduction of near-infrared light (photons) through the intact skull via their 
differing photon absorption properties. The continuous-wave NIRS ma- chine utilises the 
scattering and absorption information of photons to calculate relative concentration 
changes (μmol/L) in oxy-Hb, deoxy-Hb and total-Hb (the latter calculated by adding 
together oxy and deoxy) by means of a modified Beer-Lambert law. When assessed by 
NIRS, the increase in CBF in the surface layers of the cortex during localised neural activity 
is typically seen as an in- crease in the total concentration of haemoglobin (total-Hb) 
and comparative decrease in deoxy-Hb with both parameters corresponding strongly 
with the fMRI BOLD signal.  
 
Both fMRI and NIRS have strengths and weaknesses when compared. For example, NIRS is a 
more convenient and less expensive method that offers finer temporal resolution than 
fMRI. On the other hand, fMRI offers superior spatial resolution and decreased signal-to-
noise ratio (SNR). Overall, NIRS can be viewed as an appropriate alternative to fMRI as long 
as the spatial resolution is sufficient for answering the research question and the weaker 
SNR is accounted for in the research design. 
 
 
Figure 1. Photon path between NIRS transmitter and receiver pair. 
 
 
Relationship between N-3 PUFAs, CBF parameters and Cognition 
 
Armed with these neuroimaging tools, the relationship between n-3 PUFAs, CBF and 
cognition can be investigated and have successfully been applied across all age groups. 
For instance, McNarama et al. (2010) conducted an 8 week, randomised, double blind, 
placebo-controlled supplementation study with 3 treatment arms (placebo, 400 mg/d DHA, 
1200 mg/d DHA) on a sample of 33 partici- pants (agem 8.98 years). The study employed 
fMRI to assess relative changes in cortical activation patterns during sustained attention 
at baseline and endpoint. Significantly greater changes were observed from baseline in 
activation of the dorsolateral prefrontal cortex (PFC) in both DHA groups than the 
placebo group. Additionally, high-dose DHA was associated with decreased activation of 
the cerebellar cortex compared with both the low dose DHA and placebo conditions, which 
the authors note is the opposite pattern that had been observed in a paediatric sample 
with ADHD. Participants’ erythrocyte DHA composition was positively correlated with 
dorsolateral prefrontal cortex activation and was inversely correlated with reaction time, 
at baseline and endpoint. Taken together, these findings suggest that dietary intake of DHA 
is associated with alterations in the functional activity of cortical attention networks 
during sustained attention in children. 
Similarly, the findings presented by Jackson et al. [5] demonstrated that dietary intake 
of DHA is also associated with increased cerebral blood flow during the performance of 
cognitive tasks in young adults, as measured using NIRS. These authors conducted a 12-
week, randomised, double blind, placebo-controlled intervention study with 3 treatment 
arms (placebo, 1 g DHA and 2 g DHA rich fish oil (n = 65, agem = 20.6 years). Akin to the 
findings of the study by McNamara et al. (2010), these authors did not report any 
interpretable effects of the intervention on cognition, despite the observed changes in 
cerebral haemodynamics in both active treatment groups. 
Another study by Hamazaki-Fujita et al. [1] also provides evidence suggesting that 
dietary intake of n-3 PUFAs may be associated with cerebral haemodynamic parameters 
in younger individuals. These authors assessed the relationship between n-3 PUFAs and 
human cerebral blood oxygenation in a sample of 54, healthy young adults (agem = 34 
years). Using NIRS, the researchers identified that EPA was positively associated with tissue 
oxygen index (a simplified index for cerebral blood circulation), which in turn was 
positively associated with arousal level and inversely associated with negative mood 
(POMS). DHA and EPA were inversely associated with depression–dejection (POMS) and 
positively associated with arousal level and overall performance in the Uchida-Kraepelin 
Performance test of mental arithmetic. The researchers concluded that EPA increased 
the oxygenation level in the PFC, in turn improving various psychological parameters 
and cognitive performance. 
In contrast, a modulating effect of n-3 PUFAs has not been demonstrated in older 
adults using NIRS. Recently, Jackson et al. [6] conducted a 26-week, randomised, double 
blind, placebo-con- trolled intervention study with 3 treatment groups (placebo, 2 g 
DHA rich fish oil, 2 g DHA rich fish oil with added multinutrients) on a sample of 84 healthy 
adults (agem = 59.68 years). No effect of either active treatment was found for any of 
the NIRS outcome measures or on the cognitive performance tasks. Similarly, van de Rest 
et al. [7] conducted a 4-week, randomised, double blind, placebo-controlled 
supplementation study in  20  participants (agem = 73.1 years) with mild cognitive 
impairment (MCI). Daily supplementation with 3 g/d EPA+DHA for 4 weeks was found to 
have no effect on cerebral haemodynamics as measured using NIRS or blood pressure. 
All subjects improved on most of the neuropsychological tests, but there was no 
difference between the active and the placebo groups. Taken together, these results are 
interesting as they suggest that the previously [1] reported cerebral haemodynamic 
effects of n-3 PUFAs may be specific to younger individuals. A recent study by Witte et al. 
[8] revealed that one potential reason underpinning these null effects could be that in 
ageing, the rapid delivery of oxygen and nutrients to the cortex in response to increased 
cognitive activity becomes less important in comparison to the increased need to 
maintain the overall structural integrity of the brain. These researchers conducted a 
randomised, double-blind, interventional study with two treatment groups (placebo, 
1320 mg EPA + 880 mg DHA) in 65 healthy adults (agem = 63.9 years). The authors 
reported a significant improvement in executive function following the active treatment 
compared to placebo after the 26- week intervention. In addition, n-3 PUFAs were 
associated with beneficial effects on white matter microstructural integrity and grey 
matter volume in frontal, temporal, parietal and limbic areas primarily in the left 
hemisphere, as measured by MRI. 
 
Conclusions 
 
Taking the literature concerning the relationship between n-3 PU- FAs and cognitive 
function as a whole, conflicting data regarding the benefit of dietary n-3 PUFAs on 
cognitive function have been collected from cross-sectional studies and randomised 
controlled trials (RCTs). Whilst population-based studies have consistently indicated that 
higher intake of n-3 PUFAs is associated with better cognitive function and lower 
incidence of cognitive decline and dementia, the results from RCTs have been equivocal. 
The application of neuroimaging techniques such as fMRI and NIRS in this field have 
indicated that in the case of younger individuals, supple- mentation with n-3 PUFAs is 
associated with observable differences in brain function, even when no changes in 
behaviour are detected. This suggests that functional changes in the brain are subtle to 
the point where longer intervention periods are necessary to assess the effect of n-3 
PUFAs on cognition, or indeed are only observable over the course of a lifetime. It may 
not be a coincidence then that the only study in healthy younger adults to demonstrate a 
benefit of n-3 PUFA supplementation over placebo on cognition administered treatment 
over a period of 6 months [9]. 
When evaluating the neuroimaging data gleaned from intervention studies in older 
adults, the picture is less clear. To date, no evidence of an effect of n-3 PUFA 
supplementation on CBF para- meters as measured using NIRS has been detected in this 
population, even following a 6-month intervention [6]. Evidence from the study 
conducted by Witte et al. [8] suggests perhaps that the lack of evidence in favour of 
modulation of CBF parameters in older adults may be due to the neurological changes 
that occur during ageing, although this suggestion requires further exploration. On the 
other hand, it must also be considered that global changes in CBF – which may be 
modulated by n-3 PUFA supplementation – cannot be adequately assessed with 
continuous wave NIRS systems which have hitherto been utilised [6, 7], as only relative 
changes in the concentration of oxy- and deoxy-Hb rather than absolute changes in 
these parameters are measured with these devices. The adoption of so-called 
‘quantitative NIRS’ systems which do collect absolute change data in CBF parameters will 
be able to assess whether gross changes in CBF occur in older adults following n-3 PUFAs 
in future studies as these systems become more widely available. More- over, as 
measuring with NIRS offers a number of advantages over fMRI, it is important that 
investigation with this technique continues, and its ability to be used in the early 
detection of cognitive decline along with early effects of n-3 PUFAs is explored in more 
detail. To this end, greater focus on the effects of n-3 PUFAs on brain function and 
behaviour in middle-aged adults – a population which has up till now been relatively 
neglected by the literature – may therefore be required. Finally, whilst many studies 
have focussed on the effects of DHA on brain function, the results presented by 
Hamazaki-Fujita et al. [1] and Witte et al. [8] suggest that the role of dietary EPA on 
these outcomes should not be over- looked. 
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